STX shows the highest concentration of crypto trading in Korea, with its domestic trading volume 26.9 times larger than overseas. ONDO leads in overall interest and INJ sees the biggest trading surge. The data highlights differing domestic and overseas trading shares for 53 crypto assets, revealing strong local preferences and notable price premiums like SHIB's 0.74% kimchi premium. These trends reflect Korea's unique crypto market dynamics and investor behavior.
The story on STX's Korean trading share provides context for readers following cryptocurrency markets. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 06, 2026 21:21 WIB: out of 50 major cryptocurrencies, 6 rose and 43 fell today. ONE (Harmony) gained 33.31% with a typical hold time of 154 days, while SXP (Solar) dropped 46.27% with a typical hold time of 94 days.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
